Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Dry Eye Syndrome
Interventions
DRUG

AVX012 Ophthalmic Solution Low dose

Ocular topical administration of AVX Ophthalmic Solution Low dose

DRUG

AVX012 Ophthalmic Solution High dose

Ocular topical administration of AVX Ophthalmic Solution High dose

DRUG

Placebo (vehicle)

Ocular topical administration of placebo (vehicle Ophthalmic Solution)

Trial Locations (21)

11407

NOT_YET_RECRUITING

Clinica Oftalvist Jerez, Jerez de la Frontera

18004

NOT_YET_RECRUITING

clínica Oftalvist Granada, Granada

28027

NOT_YET_RECRUITING

Clínica Universitaria de Navarra_ Madrid, Madrid

28028

NOT_YET_RECRUITING

Clínica Oftalvist Moncloa, Madrid

28034

RECRUITING

H Universitario Ramón y Cajal, Madrid

28040

RECRUITING

H Clínico San Carlos, Madrid

30003

RECRUITING

Hospital General Universitario Reina Sofía, Murcia

31008

RECRUITING

Clínica Universitaria de Navarra, Pamplona

33012

RECRUITING

Instituto Oftalmológico Fernández Vega, Oviedo

46004

NOT_YET_RECRUITING

clinica Oftalvist Valencia, Valencia

46026

NOT_YET_RECRUITING

Hospital Universitario La Fé, Valencia

47011

RECRUITING

Instituto Universitario de Oftalmobiología Aplicada (IOBA), Valladolid

50004

RECRUITING

H Miguel Servet, Zaragoza

50009

RECRUITING

H Universitario Lozano Blesa, Zaragoza

03015

NOT_YET_RECRUITING

Clínica Oftalvist Vistahermosa, Alicante

08006

RECRUITING

Innova Ocular ICO Barcelona, Barcelona

08021

NOT_YET_RECRUITING

Centro de Oftalmologia Barraquer, Barcelona

08035

NOT_YET_RECRUITING

H Vall de Hebron, Barcelona

08036

RECRUITING

H Clinic, Barcelona

08190

RECRUITING

H General de Cataluña, Barcelona

08916

NOT_YET_RECRUITING

H Germas Trias Pujol, Barcelona

Sponsors
All Listed Sponsors
lead

Avizorex Pharma, S.L.

INDUSTRY

NCT03162094 - Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome | Biotech Hunter | Biotech Hunter